| Literature DB >> 33860747 |
Arnaud Fontanet1,2, Laura Tondeur1, Rebecca Grant1, Sarah Temmam3, Yoann Madec1, Thomas Bigot4, Ludivine Grzelak5,6,7, Isabelle Cailleau8, Camille Besombes1, Marie-Noëlle Ungeheuer9, Charlotte Renaudat9, Blanca Liliana Perlaza9, Laurence Arowas9, Nathalie Jolly10, Sandrine Fernandes Pellerin10, Lucie Kuhmel11, Isabelle Staropoli12,5,6, Christèle Huon3, Kuang-Yu Chen13, Bernadette Crescenzo-Chaigne14,6,7, Sandie Munier14,6,7, Pierre Charneau15,16, Caroline Demeret14, Timothée Bruel12,5,6, Marc Eloit17,3, Olivier Schwartz12,5,6, Bruno Hoen1,8.
Abstract
BackgroundChildren's role in SARS-CoV-2 epidemiology remains unclear. We investigated an initially unnoticed SARS-CoV-2 outbreak linked to schools in northern France, beginning as early as mid-January 2020.AimsThis retrospective observational study documents the extent of SARS-CoV-2 transmission, linked to an affected high school (n = 664 participants) and primary schools (n = 1,340 study participants), in the context of unsuspected SARS-CoV-2 circulation and limited control measures.MethodsBetween 30 March and 30 April 2020, all school staff, as well as pupils and their parents and relatives were invited for SARS-CoV-2 antibody testing and to complete a questionnaire covering symptom history since 13 January 2020.ResultsIn the high school, infection attack rates were 38.1% (91/239), 43.4% (23/53), and 59.3% (16/27), in pupils, teachers, and non-teaching staff respectively vs 10.1% (23/228) and 12.0% (14/117) in the pupils' parents and relatives (p < 0.001). Among the six primary schools, three children attending separate schools at the outbreak start, while symptomatic, might have introduced SARS-CoV-2 there, but symptomatic secondary cases related to them could not be definitely identified. In the primary schools overall, antibody prevalence in pupils sharing classes with symptomatic cases was higher than in pupils from other classes: 15/65 (23.1%) vs 30/445 (6.7%) (p < 0.001). Among 46 SARS-CoV-2 seropositive pupils < 12 years old, 20 were asymptomatic. Whether past HKU1 and OC43 seasonal coronavirus infection protected against SARS-CoV-2 infection in 6-11 year olds could not be inferred.ConclusionsViral circulation can occur in high and primary schools so keeping them open requires consideration of appropriate control measures and enhanced surveillance.Entities:
Keywords: Coronavirus disease 2019 (COVID-19); Emerging infectious diseases; Epidemiology; SARS-CoV-2
Mesh:
Year: 2021 PMID: 33860747 PMCID: PMC8167414 DOI: 10.2807/1560-7917.ES.2021.26.15.2001695
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
Infection attack rates among participants of investigations documenting the extent of SARS-CoV-2 transmission in a high school and primary schools, northern France, 30 March–30 April 2020 (n = 2,004 participants)
| Characteristic | High school investigation (n = 664) | Primary school investigation (n = 1,340) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total number | Number of | Per cent seropositive | p | Total number | Number of | Per cent seropositive | p | ||
| Male | 253 | 54 | 21.3 | 0.08 | 571 | 54 | 9.5 | 0.34 | |
| Female | 411 | 113 | 27.5 | 769 | 85 | 11.1 | |||
| < 12 | 8 | 0 | 0.0 | < 0.001 | 538 | 46 | 8.6 | 0.10 | |
| 12–17 | 235 | 82 | 34.9 | 78 | 12 | 15.4 | |||
| ≥ 18 | 421 | 85 | 20.2 | 724 | 81 | 11.2 | |||
| Pupil | 239 | 91 | 38.1 | < 0.001 | 510 | 45 | 8.8 | 0.36 | |
| Teacher | 53 | 23 | 43.4 | 41 | 3 | 7.3 | |||
| Non-teaching staff | 27 | 16 | 59.3 | 28 | 1 | 3.6 | |||
| Parents | All | 228 | 23 | 10.1 | 642 | 76 | 11.8 | ||
| Of an infected pupil | 82 | 15 | 18.3 | 59 | 36 | 61.0 | |||
| Of a non-infected pupil | 132 | 7 | 5.3 | 569 | 39 | 6.9 | |||
| Other | 14 | 1 | 7.1 | 14 | 1 | 7.1 | |||
| Relatives | All | 117 | 14 | 12.0 | 119 | 14 | 11.8 | ||
| Of an infected pupil | 50 | 10 | 20.0 | 9 | 4 | 44.4 | |||
| Of a non-infected pupil | 65 | 2 | 3.1 | 107 | 10 | 9.3 | |||
| Other | 2 | 2 | 100.0 | 3 | 0 | 0.0 | |||
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
Figure 1Timeline of symptom onset among (A) 143 symptomatic cases who were seropositive for SARS-CoV-2 antibodies in a high school and (B) 107 symptomatic cases who were seropositive for SARS-CoV-2 antibodies in primary schools, investigation in a city in northern France, 13 January–19 April 2020 (n = 250)
Proportion of pupils with SARS-CoV-2 antibodies by class and by primary school in a city in northern France, 13 January–19 April 2020 (n = 510)
| School | Class and proportion of pupils with SARS-CoV-2 antibodies | All classes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CP | CP/CE1a | CE1 | CE1/CE2a | CE2 | CE2/CM1a | CM1 | CM1/CM2a | CM2 | |||
| Proportion | Proportion | Proportion | Proportion | Proportion | Proportion | Proportion | Proportion | Proportion | Proportion | % | |
| A | 1/7 | 0/8 | 0/7 | NA | 0/9 | NA | 0/10 | 1/12 | 0/8 | 2/61 | 3.3 |
| B | 2/17 | 0/1 | NA | 1/32 | NA | 3/18 | NA | 5/22 | NA | 11/90 | 12.2 |
| C | 0/12 | NA | 3/10 | NA | 1/14 | NA | NA | 10/32 | NA | 14/68 | 20.6 |
| D | 0/8 | 0/8 | 1/13 | 0/9 | 1/11 | NA | 1/24 | 0/1 | 1/12 | 4/87b | 4.6 |
| E | 0/12 | 2/28 | NA | 0/9 | 2/15 | NA | 2/15 | 0/25 | 0/13 | 6/117 | 5.1 |
| F | 0/16 | NA | 1/11 | NA | 2/18 | NA | 4/22 | NA | 1/20 | 8/87 | 9.2 |
CE1: cours élémentaire première année; CE2: cours élémentaire deuxième année; CM1: cours moyen première année; CM2: cours moyen deuxième année; CP: cours préparatoire; NA: not applicable (the school in question had few pupils so there were no children populating the class in question); SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
The classes CP, CE1, CE2, CM1, CM2 respectively correspond to the first to fifth years (levels) of primary school. Shaded areas: classes with one documented symptomatic introduction.
a These are classes combining two levels.
b Class missing for one child.
SARS-CoV-2 infection attack rates (%) by symptoms and age category in schools in a city in northern France, 13 January–19 April 2020 (n = 2,004 participants)
| Symptoms | Children < 12 years (n = 546) | Children 12–17 years (n = 313) | Adults (n = 1,145) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Proportion with the symptom | Number infected | Proportion with the symptom infected | p value | Number | Proportion with the symptom | Number infected | Proportion with the symptom infected | p value | Number | Proportion with the symptom | Number infected | Proportion with the symptom infected | p value | |
| Yes | 121 | 22.2 | 13 | 10.7 | 0.30 | 84 | 26.8 | 33 | 39.3 | 0.03 | 254 | 22.2 | 81 | 31.9 | < 0.001 |
| No | 425 | 77.8 | 33 | 7.8 | 229 | 73.2 | 61 | 26.6 | 891 | 77.8 | 85 | 9.5 | |||
| Yes | 124 | 22.7 | 8 | 6.5 | 0.37 | 105 | 32.9 | 32 | 30.5 | 0.90 | 349 | 30.5 | 87 | 24.9 | < 0.001 |
| No | 422 | 77.3 | 38 | 9.0 | 208 | 66.5 | 62 | 29.8 | 796 | 69.5 | 79 | 9.9 | |||
| Yes | 20 | 3.7 | 3 | 15.0 | 0.28 | 33 | 10.5 | 5 | 15.1 | 0.05 | 157 | 13.7 | 49 | 31.2 | < 0.001 |
| No | 526 | 96.3 | 43 | 8.2 | 280 | 89.5 | 89 | 31.8 | 988 | 86.3 | 117 | 11.8 | |||
| Yes | 4 | 0.7 | 0 | 0 | 0.99 | 19 | 6.1 | 17 | 89.5 | < 0.001 | 94 | 8.2 | 76 | 80.9 | < 0.001 |
| No | 542 | 99.3 | 46 | 8.5 | 294 | 93.9 | 77 | 26.2 | 1,051 | 91.7 | 90 | 8.6 | |||
| Yes | 2 | 0.4 | 0 | 0 | 0.99 | 20 | 6.4 | 16 | 80.0 | < 0.001 | 85 | 7.4 | 76 | 89.4 | < 0.001 |
| No | 544 | 99.6 | 46 | 8.5 | 293 | 93.6 | 78 | 26.6 | 1,060 | 92.6 | 90 | 8.5 | |||
| Yes | 40 | 7.3 | 4 | 10.0 | 0.71 | 55 | 17.6 | 19 | 34.5 | 0.42 | 268 | 23.4 | 83 | 31.0 | < 0.001 |
| No | 506 | 92.7 | 42 | 8.3 | 258 | 82.4 | 75 | 29.1 | 877 | 76.6 | 83 | 9.5 | |||
| Yes | 90 | 16.5 | 8 | 8.9 | 0.86 | 87 | 27.8 | 25 | 28.7 | 0.76 | 261 | 22.8 | 53 | 20.3 | 0.002 |
| No | 456 | 83.5 | 38 | 8.3 | 226 | 72.2 | 69 | 30.5 | 884 | 77.2 | 113 | 12.8 | |||
| Yes | 97 | 17.8 | 10 | 10.3 | 0.46 | 114 | 36.4 | 41 | 36.0 | 0.08 | 283 | 24.7 | 62 | 21.9 | < 0.001 |
| No | 449 | 82.2 | 36 | 8.0 | 199 | 63.5 | 53 | 26.6 | 862 | 75.3 | 104 | 12.1 | |||
| Yes | 101 | 18.5 | 8 | 7.9 | 0.84 | 91 | 29.1 | 31 | 34.1 | 0.32 | 332 | 29.0 | 84 | 25.3 | < 0.001 |
| No | 445 | 81.5 | 38 | 8.5 | 222 | 70.9 | 63 | 28.4 | 813 | 71.0 | 82 | 10.1 | |||
| Yes | 79 | 14.4 | 11 | 13.9 | 0.06 | 77 | 24.6 | 26 | 33.8 | 0.41 | 350 | 30.6 | 95 | 27.1 | < 0.001 |
| No | 467 | 85.5 | 35 | 7.5 | 236 | 75.4 | 68 | 28.8 | 795 | 69.4 | 71 | 8.9 | |||
| Yes | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | - | 7 | 0.6 | 0 | 0 | 0.61 |
| No | 546 | 100 | 46 | 8.4 | 313 | 100 | 94 | 30.0 | 1,138 | 99.4 | 166 | 14.6 | |||
| Yes | 3 | 0.5 | 1 | 33.3 | 0.23 | 3 | 1.0 | 2 | 66.7 | 0.22 | 10 | 0.9 | 4 | 40.0 | 0.04 |
| No | 543 | 99.5 | 45 | 8.3 | 310 | 99.0 | 92 | 29.7 | 1,135 | 99.1 | 162 | 14.3 | |||
| Yes | 23 | 4.2 | 1 | 4.3 | 0.71 | 13 | 4.2 | 5 | 38.5 | 0.54 | 18 | 1.6 | 2 | 11.1 | 0.99 |
| No | 523 | 95.8 | 45 | 8.6 | 300 | 95.8 | 89 | 29.7 | 1,127 | 98.4 | 164 | 14.6 | |||
| Yes | 6 | 1.1 | 0 | 0 | 0.99 | 2 | 0.6 | 0 | 0 | 0.99 | 12 | 1.0 | 4 | 33.3 | 0.08 |
| No | 540 | 98.9 | 46 | 8.5 | 311 | 99.4 | 94 | 30.2 | 1,133 | 99.0 | 162 | 14.3 | |||
| Yes | 50 | 9.2 | 9 | 18.0 | 0.01 | 37 | 11.8 | 17 | 45.9 | 0.03 | 151 | 13.2 | 38 | 25.2 | < 0.001 |
| No | 496 | 90.8 | 37 | 7.5 | 276 | 88.2 | 77 | 27.9 | 994 | 86.8 | 128 | 12.9 | |||
| None | 274 | 50.2 | 20 | 7.3 | 0.62 | 110 | 35.1 | 22 | 20.0 | 0.01 | 429 | 37.5 | 14 | 3.3 | < 0.001 |
| Minora only | 89 | 16.3 | 8 | 9.0 | 54 | 17.3 | 15 | 27.8 | 214 | 18.7 | 14 | 6.5 | |||
| Majorb | 183 | 33.5 | 18 | 9.8 | 149 | 47.6 | 57 | 38.3 | 502 | 43.8 | 138 | 27.5 | |||
| Yes | 99 | 36.4 | 8 | 8.1 | 0.53 | 44 | 21.7 | 17 | 38.6 | 0.62 | 255 | 35.6 | 73 | 28.6 | < 0.001 |
| No | 173 | 63.6 | 18 | 10.4 | 159 | 78.3 | 55 | 34.6 | 461 | 64.4 | 79 | 17.1 | |||
| Yes | 1 | 0.2 | 0 | 0 | 0.99 | 4 | 1.3 | 2 | 50.0 | 0.59 | 14 | 1.2 | 9 | 64.3 | < 0.001 |
| No | 545 | 99.8 | 46 | 8.5 | 309 | 98.7 | 92 | 29.8 | 1,131 | 98.8 | 157 | 13.9 | |||
NA: not applicable.
a Minor symptoms included asthenia, diarrhoea, headache, myalgia, rhinitis, and sore throat.
b Major symptoms included ageusia and anosmia, fever, dry cough and dyspnoea.
Only among participants who declared symptoms, including children < 12 years (n = 272); children 12–17 years (n = 203); adults (n = 716).
Figure 2SARS-CoV-2 and seasonal HCoV antibody responses by LIPS in children with (n = 49) and without (n = 98) SARS-CoV-2 neutralising antibodies